KPF
RVPH

K2 Principal Fund’s REVIVA PHARMA HLDGS INC RVPH Stock Holding History

K2 Principal Fund’s Portfolio RVPH Stock Details RVPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-1,168
Closed -$246K – 301
2020
Q1 		$246K Buy
+1,168
New +$245K 0.05% 180
2019
Q2 		– Sell
-3,750
Closed -$755K – 321
2019
Q1 		$755K Buy
+3,750
New +$752K 0.1% 207

Other funds holding RVPH

Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
MSU
Mizuho Securities USA New York $4.24B AUM 22.54% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return
PC
Periscope Capital Toronto, Ontario, Canada $902M AUM 6.51% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
WRBC
W.R. Berkley Corp Greenwich, Connecticut $1.86B AUM 14.44% 1-Year Est. Return
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
GCIA
Gabelli & Co Investment Advisers Rye, New York $674M AUM 64.52% 1-Year Est. Return
GF
Gabelli Funds Rye, New York $14.8B AUM 32.24% 1-Year Est. Return

K2 Principal Fund's RVPH Position: Q2 2020 in Review

K2 Principal Fund sold out of REVIVA PHARMA HLDGS INC (RVPH) in Q2 2020, closing a stake of 1,168 shares — an estimated $246K sold.

K2 Principal Fund first reported a position in RVPH in Q1 2019 and held it in 2 quarters. The position peaked at $755K in Q1 2019. 16 funds tracked by Wall St. Rank hold RVPH as of Q2 2020.

  • K2 Principal Fund reported no remaining REVIVA PHARMA HLDGS INC position as of Q2 2020 after selling out during the quarter.
  • K2 Principal Fund sold 1,168 REVIVA PHARMA HLDGS INC shares in Q2 2020, an estimated $246K.
  • K2 Principal Fund first reported a position in REVIVA PHARMA HLDGS INC in Q1 2019 and held it in 2 quarters.
  • K2 Principal Fund's REVIVA PHARMA HLDGS INC position peaked at $755K in Q1 2019.
  • 16 funds tracked by Wall St. Rank held REVIVA PHARMA HLDGS INC as of Q2 2020.

Based on K2 Principal Fund's 13F filing for Q2 2020, filed 13 Aug 2020.